Patient Preferences for Attributes of Type 2 Diabetes Mellitus Medications in Germany and Spain: An Online Discrete-Choice Experiment Survey

Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
Carol MansfieldAlan A Martin

Abstract

Understanding patient preferences for attributes of type 2 diabetes mellitus (T2DM) medications may help explain how the attributes differentially affect patient perceptions and behaviors. In this survey, we quantified the relative preferences among patients in Germany and Spain in separate analyses. A stated-preference, discrete-choice experiment (DCE) survey was designed to elicit preferences for T2DM treatment attributes among patients with self-reported T2DM and who reported being prescribed T2DM medication for > 2 years. Patients recruited from an online national consumer panel completed an online survey. The survey presented choices between eight pairs of hypothetical T2DM treatments defined by seven attributes: chance of reaching target hemoglobin A1c (HbA1c) level; reduced risk of serious heart attack or stroke; frequency of hypoglycemia; risk of gastrointestinal (GI) problems; weight change; mode of administration (oral or injectable); dosing frequency. Data were analyzed using random-parameters logit. Minimum acceptable benefit (MAB) was defined as the minimum increase in the probability of reaching target HbA1c for which respondents would accept less desirable levels of other attributes. In Germany and Spain, 474 and...Continue Reading

References

Apr 21, 2004·The Diabetes Educator·Bruce BodeUNKNOWN InDuo Study Group
Aug 27, 2005·Diabetes Care·A Brett HauberBenedicte Lescrauwaet
Jun 15, 2011·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·John F P BridgesJosephine Mauskopf
Sep 21, 2011·Journal of the National Cancer Institute·Angela FagerlinPeter A Ubel
Aug 11, 2012·European Journal of Epidemiology·Ralph BrinksWolfgang Rathmann
Jan 23, 2013·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·F Reed JohnsonJohn F P Bridges
Nov 21, 2013·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Christine PoulosMark A Deeg
Dec 5, 2013·Diabetes Research and Clinical Practice·T TamayoW Rathmann
Jun 26, 2014·Diabetes Care·Tanjala S PurnellNisa Maruthur
Jul 10, 2014·PharmacoEconomics·Michael D ClarkEsther W de Bekker-Grob
Jan 6, 2016·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Alan J GarberUNKNOWN American College of Endocrinology (ACE)

❮ Previous
Next ❯

Citations

Jun 10, 2019·Diabetes Care·Bruce A PerkinsNima Soleymanlou
Jun 14, 2020·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Aude Roborel de ClimensAlka Shaunik
Apr 17, 2020·PharmacoEconomics·Juan M Ramos-GoñiNancy Devlin
Jan 4, 2020·Journal of General Internal Medicine·Thomas KaragiannisEleni Bekiari
Jan 1, 2020·Journal of Diabetes and Metabolic Disorders·Mahdi ToroskiShekoufeh Nikfar
Nov 4, 2020·The Patient·Alison PearceStirling Bryan

❮ Previous
Next ❯

Software Mentioned

NLOGIT
SAS

Related Concepts

Related Feeds

Anxiety Disorders

Discover the latest research on anxiety disorders including agoraphobia, panic disorder, obsessive-compulsive disorder, and post-traumatic stress disorder here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.